Last edition
News about "GLP-1/GIP receptor agonist"
Roche Reports Positive Phase 2 Results for Enicepatide
Roche has announced positive phase 2 results for dual GLP-1/GIP receptor agonist enicepatide in people living with Type 2 Diabetes and overweight or obesity.
GLP-1/GIP Receptor Agonist | 23/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members